- Home
- MAX vs KROS Comparison
MAX vs KROS Comparison
Compare MAX & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAX
- KROS
- Stock Information
- Founded
- MAX 2014
- KROS 2015
- Country
- MAX United States
- KROS United States
- Employees
- MAX N/A
- KROS N/A
- Industry
- MAX Industrial Machinery/Components
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- MAX Industrials
- KROS Health Care
- Exchange
- MAX Nasdaq
- KROS Nasdaq
- Market Cap
- MAX 582.4M
- KROS 558.9M
- IPO Year
- MAX 2020
- KROS 2020
- Fundamental
- Price
- MAX $10.44
- KROS $14.28
- Analyst Decision
- MAX Strong Buy
- KROS Buy
- Analyst Count
- MAX 6
- KROS 13
- Target Price
- MAX $17.92
- KROS $20.63
- AVG Volume (30 Days)
- MAX 394.0K
- KROS 467.7K
- Earning Date
- MAX 07-30-2025
- KROS 08-06-2025
- Dividend Yield
- MAX N/A
- KROS N/A
- EPS Growth
- MAX N/A
- KROS N/A
- EPS
- MAX 0.28
- KROS 0.11
- Revenue
- MAX $1,002,364,000.00
- KROS $214,713,000.00
- Revenue This Year
- MAX $24.09
- KROS $5,006.76
- Revenue Next Year
- MAX $11.18
- KROS N/A
- P/E Ratio
- MAX $37.11
- KROS $131.15
- Revenue Growth
- MAX 148.62
- KROS 91657.70
- 52 Week Low
- MAX $7.33
- KROS $9.12
- 52 Week High
- MAX $20.91
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- MAX 49.08
- KROS 63.37
- Support Level
- MAX $10.28
- KROS $13.26
- Resistance Level
- MAX $11.14
- KROS $14.83
- Average True Range (ATR)
- MAX 0.34
- KROS 0.40
- MACD
- MAX -0.06
- KROS 0.13
- Stochastic Oscillator
- MAX 39.21
- KROS 79.87
About MAX MediaAlpha Inc.
MediaAlpha Inc provides a platform that facilitates insurance carriers and distributors target and acquire customers. The company's technology platform brings insurance carriers and consumers together through a real-time, transparent, and results-driven ecosystem. It acts as a customer acquisition channel in the areas of property & casualty insurance, health insurance, and life insurance. It operates in the United States and generates revenue by earning a fee for each consumer referral sold on its platform.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.